A New York biotech announced Tuesday that its experimental treatment for ALS did not meet the main goal of a late-stage clinical trial, dealing the latest blow to a research field marred by drug failures.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,